(Total Views: 482)
Posted On: 03/03/2021 2:27:33 PM
Post# of 153903
Z_Smith,
Exactly. You get the point.
What is more, RANTES binds to both CCR5 and CCR1.
So our antagonist is for sure addressing one of the the therapeutic targets (and maybe both). I have not been able to confirm that VX could be antagonist of CCR1, however the fact that CCL4 binds to CCR1 and does not activate it chemoattractant status is "telling" in that CCR5 is the important receptor in COVID.
This paper is a real treasure in which it points to our moa as the target. So we are fighting in the field were everybody should be
, and hopefully winning.
Quote:
leaving CCR1 and/or CCR5 as potential therapeutic targets
Exactly. You get the point.
What is more, RANTES binds to both CCR5 and CCR1.
So our antagonist is for sure addressing one of the the therapeutic targets (and maybe both). I have not been able to confirm that VX could be antagonist of CCR1, however the fact that CCL4 binds to CCR1 and does not activate it chemoattractant status is "telling" in that CCR5 is the important receptor in COVID.
This paper is a real treasure in which it points to our moa as the target. So we are fighting in the field were everybody should be
, and hopefully winning.
(5)
(0)
